StreetInsider.com News Articles

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Thu, 18 Jun 2026 15:54:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 18, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Thu, 18 Jun 2026 15:54:00 -0400

Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders

Thu, 18 Jun 2026 08:16:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.

What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and directors failed to implement and maintain adequate internal controls and oversight mechanisms concerning the Company's revenue recognition practices, related-party transactions, and public disclosures.

If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back

Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders

Thu, 18 Jun 2026 08:16:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.
What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and directors failed to implement and maintain adequate internal controls and oversight mechanisms concerning the Company's revenue recognition practices, related-party transactions, and public disclosures.
If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 17 Jun 2026 15:48:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 17 Jun 2026 15:48:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 16 Jun 2026 15:44:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 16, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 16 Jun 2026 15:44:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 16, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 15 Jun 2026 14:34:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 15 Jun 2026 14:34:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 12 Jun 2026 17:26:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 12, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 12 Jun 2026 17:26:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 12, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics Investors Should Contact Block & Leviton By August 10th to Lead Class Action Lawsuit

Thu, 11 Jun 2026 15:09:00 -0400

Boston, Massachusetts--(Newsfile Corp. - June 11, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its executives. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.
What is this all about?
The complaint alleges that ADMA Biologics misled investors about the source of its revenue growth by engaging in a channel-stuffing scheme involving its flagship product, ASCENIV, and by failing to disclose an alleged related-party

ADMA Biologics Investors Should Contact Block & Leviton By August 10th to Lead Class Action Lawsuit

Thu, 11 Jun 2026 15:09:00 -0400

Boston, Massachusetts--(Newsfile Corp. - June 11, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its executives. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.
What is this all about?
The complaint alleges that ADMA Biologics misled investors about the source of its revenue growth by engaging in a channel-stuffing scheme involving its flagship product, ASCENIV, and by failing to disclose an alleged related-party

Raymond James Starts ADMA Biologics (ADMA) at Outperform

Wed, 10 Jun 2026 07:03:43 -0400

Raymond James analyst Ryan Deschner initiates coverage on ADMA Biologics (NASDAQ: ADMA) with a Outperform rating and a price target of $21.00.
The analyst comments "We are resuming coverage of ADMA Biologics with an Outperform rating and $21 price target. ADMA develops and manufactures intravenous immunoglobulin (IVIG) therapies in the U.S., primarily for patients with primary humoral immunodeficiency (PI). A clearly defined capitalefficient strategy, continuous innovation, and current focus on penetrating the refractory PI market (currently only ~4% penetrated per management) with its highest margin product, ASCENIV, has transformed ADMA into a profitable, high-growth company over just the last few years,

Raymond James Starts ADMA Biologics (ADMA) at Outperform

Wed, 10 Jun 2026 07:03:43 -0400

Raymond James analyst Ryan Deschner initiates coverage on ADMA Biologics (NASDAQ: ADMA) with a Outperform rating and a price target of $21.00.
The analyst comments "We are resuming coverage of ADMA Biologics with an Outperform rating and $21 price target. ADMA develops and manufactures intravenous immunoglobulin (IVIG) therapies in the U.S., primarily for patients with primary humoral immunodeficiency (PI). A clearly defined capitalefficient strategy, continuous innovation, and current focus on penetrating the refractory PI market (currently only ~4% penetrated per management) with its highest margin product, ASCENIV, has transformed ADMA into a profitable, high-growth company over just the last few years,

Raymond James Starts ADMA Biologics (ADMA) at Outperform

Wed, 10 Jun 2026 07:03:43 -0400

Raymond James analyst Ryan Deschner initiates coverage on ADMA Biologics (NASDAQ: ADMA) with a Outperform rating and a price target of $21.00.
The analyst comments "We are resuming coverage of ADMA Biologics with an Outperform rating and $21 price target. ADMA develops and manufactures intravenous immunoglobulin (IVIG) therapies in the U.S., primarily for patients with primary humoral immunodeficiency (PI). A clearly defined capitalefficient strategy, continuous innovation, and current focus on penetrating the refractory PI market (currently only ~4% penetrated per management) with its highest margin product, ASCENIV, has transformed ADMA into a profitable, high-growth company over just the last few years,

Raymond James Starts ADMA Biologics (ADMA) at Outperform

Wed, 10 Jun 2026 07:03:43 -0400

Raymond James analyst Ryan Deschner initiates coverage on ADMA Biologics (NASDAQ: ADMA) with a Outperform rating and a price target of $21.00.
The analyst comments "We are resuming coverage of ADMA Biologics with an Outperform rating and $21 price target. ADMA develops and manufactures intravenous immunoglobulin (IVIG) therapies in the U.S., primarily for patients with primary humoral immunodeficiency (PI). A clearly defined capitalefficient strategy, continuous innovation, and current focus on penetrating the refractory PI market (currently only ~4% penetrated per management) with its highest margin product, ASCENIV, has transformed ADMA into a profitable, high-growth company over just the last few years,

Form 8-K ADMA BIOLOGICS, INC. For: Jun 02

Tue, 02 Jun 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260602/26591573.html

Form 8-K ADMA BIOLOGICS, INC. For: Jun 02

Tue, 02 Jun 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260602/26591573.html

Form 4 ADMA BIOLOGICS, INC. For: May 27 Filed by: Grossman Jerrold B

Thu, 28 May 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260528/26567193.html

Form 4 ADMA BIOLOGICS, INC. For: May 27 Filed by: Grossman Jerrold B

Thu, 28 May 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260528/26567193.html

Form 4 ADMA BIOLOGICS, INC. For: May 12 Filed by: Grossman Jerrold B

Thu, 14 May 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260514/26489680.html

Form 4 ADMA BIOLOGICS, INC. For: May 12 Filed by: Grossman Jerrold B

Thu, 14 May 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260514/26489680.html

Form 4 ADMA BIOLOGICS, INC. For: May 11 Filed by: Grossman Jerrold B

Tue, 12 May 2026 17:23:00 -0400
si-local-file:///var/storage/secattach/20260512/26479441.html